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Experimental Section
General Remarks: All chemicals and solvents (Sigma-Aldrich, Fluka, Acros, Novabiochem, Iris Biotech GmbH) were purchased and used without any further purification, except dichloromethane, which was distilled from CaH 2 prior to use. All reactions were performed under argon or nitrogen with magnetic stirring and were monitored by thin-layer chromatography (TLC) using SIL G-25 UV254 pre-coated silica gel plates (0.25 mm thickness). Reactions under CO atmosphere were carried out in a Parr-High-Pressure reaction vessel with particular care. The ultra sonication was performed using a sonic bath (42 kHz, Bransonic, 2510E-MT, USA) at ambient temperature. TLC plates were visualized by using anisaldehyde (5% anisaldehyde in ethanol with 1% sulfuric acid) or PMA (5% phosphomolybdic acid in ethanol) solutions. Flash column chromatography was performed using BIOSOLVE silica gel (0.063-0.200 mm particle size, 20-30 g silica/1 g compound/ KieselgelMerck, 230-400 mesh, Type 9385, 60 Angström). 1 H NMR spectra were recorded at 300 MHz, 
Synthesis of the histidine modified nucleoside (3):
The TBDMS-protected nucleoside 1 (500 mg, 0.86 mmol) was suspended in THF (20 mL) in a Parr-High-Pressure reaction vessel and the protected histidine 2 (622 mg, 2.6 mmol), Et 3 N (1. was co-evaporated three times with pyridine and dried overnight under vacuum. The modified nucleoside was dissolved in dry pyridine (1-4 mL) and dry DCM (0.5-2 mL). 4,4'-dimethoxytrityl chloride, dissolved in dry pyridine (1-2 mL) and dry DCM (0.5-1 mL), was added dropwise to this solution at 0 °C. The reaction was stirred overnight at room temperature under argon atmosphere for 7 h. The reaction was quenched with anhydrous MeOH (1-2 mL) at 0 °C and the solvent was removed under reduced pressure. The remaining residue (yellow oil) was dissolved in DCM (5 mL). The organic phase was washed with 2x
sat. sol. NaHCO 3 (10 mL) and 1x with brine (10 mL). The collected organic phases were dried on Na 2 SO 4 and the solvent was evaporated in vacuo. The remaining residue was purified by flash chromatography on silica gel using a gradient of 0-5 % methanol in DCM + 1% Et 3 N to give the desired product (9-82%). General synthesis of 5-carboxamide modified analogues 7 and 11 from the corresponding protected TBDMS-protected compound 1: The protected nucleoside 1 (0.9-1.2 mmol) was suspended in THF (25 mL) in a Parr-High-Pressure reaction vessel and the protected amino acid 6 and 10, Et 3 N and Pd(PPh 3 ) 4 were added in the order listed. The reaction mixture was incubated at 70 °C under 50 psi (~4 bar) carbon monoxide for 48 h. The reaction mixture was cooled down to room temperature, filtered over celite and concentrated under vacuum. The remaining yellow oil was then purified on a silica gel column using 0-2% methanol in DCM as eluent to give the modified analogue (68-90%). 764.2814.
Experimental details of product (5):
Synthesis of the serine modified nucleoside (7):
Reaction of 5-iodo-3',5'-(O-di-tert- butyldimethylsilyl)-2'-deoxyuridine (1,
Synthesis of the lysine modified nucleoside (11):
Reaction of 5-iodo-3',5'-(O-di-tertbutyldimethylsilyl)-2'-deoxyuridine (1, 722 mg, 1.2 mmol) and the commercialy available protected lysine 10 (1.04 g, 3.5 mmol) according to the general procedure described above, gave the deprotected nucleoside 11 as a yellow foam (864 mg, 90% 
Experimental details of the deprotected product (12):
